TCT 2009 schedule: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 29: | Line 29: | ||
*'''Interviewee:''' Shamir Mehta | *'''Interviewee:''' Shamir Mehta | ||
*'''Trial: ''' CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS | *'''Trial: ''' CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS | ||
===2:00 PM=== | ===2:00 PM=== | ||
| Line 35: | Line 34: | ||
*'''Interviewee:''' John Spertus | *'''Interviewee:''' John Spertus | ||
*'''Trial: ''' NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent | *'''Trial: ''' NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent | ||
===2:30 PM=== | ===2:30 PM=== | ||
| Line 41: | Line 39: | ||
*'''Interviewee:''' Eberhard Grube | *'''Interviewee:''' Eberhard Grube | ||
*'''Trial: ''' BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent | *'''Trial: ''' BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent | ||
===3:00 PM=== | ===3:00 PM=== | ||
| Line 47: | Line 44: | ||
*'''Interviewee:''' David Allie | *'''Interviewee:''' David Allie | ||
*'''Trial: ''' CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions | *'''Trial: ''' CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions | ||
===3:30 PM=== | ===3:30 PM=== | ||
| Line 53: | Line 49: | ||
*'''Interviewee:''' Douglas Losordo | *'''Interviewee:''' Douglas Losordo | ||
*'''Trial: ''' ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina | *'''Trial: ''' ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina | ||
===4:00 PM=== | ===4:00 PM=== | ||
| Line 59: | Line 54: | ||
*'''Interviewee:''' Gary Ansel | *'''Interviewee:''' Gary Ansel | ||
*'''Trial: ''' ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting | *'''Trial: ''' ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting | ||
===4:30 PM=== | ===4:30 PM=== | ||
| Line 65: | Line 59: | ||
*'''Interviewee:''' Ran Kornowski | *'''Interviewee:''' Ran Kornowski | ||
*'''Trial: ''' | *'''Trial: ''' | ||
===5:00 PM=== | ===5:00 PM=== | ||
| Line 71: | Line 64: | ||
*'''Interviewee:''' Francesco Prati | *'''Interviewee:''' Francesco Prati | ||
*'''Trial:''' COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT | *'''Trial:''' COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT | ||
| Line 82: | Line 74: | ||
*'''Interviewee:''' William Fearon | *'''Interviewee:''' William Fearon | ||
*'''Trial: ''' FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease | *'''Trial: ''' FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease | ||
===9:00 AM=== | ===9:00 AM=== | ||
| Line 88: | Line 79: | ||
*'''Interviewee:''' Lorenz Raber | *'''Interviewee:''' Lorenz Raber | ||
*'''Trial: ''' SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents | *'''Trial: ''' SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents | ||
===9:30 AM=== | ===9:30 AM=== | ||
| Line 94: | Line 84: | ||
*'''Interviewee:''' Volker Klauss | *'''Interviewee:''' Volker Klauss | ||
*'''Trial: ''' LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer | *'''Trial: ''' LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer | ||
===10:00 AM=== | ===10:00 AM=== | ||
| Line 101: | Line 90: | ||
*'''Trial: ''' 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel | *'''Trial: ''' 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel | ||
2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention | 2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention | ||
===10:30 AM=== | ===10:30 AM=== | ||
| Line 107: | Line 95: | ||
*'''Interviewee:''' David Cohen | *'''Interviewee:''' David Cohen | ||
*'''Trial: ''' TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI | *'''Trial: ''' TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI | ||
===11:00 AM=== | ===11:00 AM=== | ||
| Line 113: | Line 100: | ||
*'''Interviewee:''' Chris Cannon | *'''Interviewee:''' Chris Cannon | ||
*'''Trial: ''' PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy | *'''Trial: ''' PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy | ||
===12:00 PM=== | ===12:00 PM=== | ||
''12:00 PM - 12:30 PM'' | ''12:00 PM - 12:30 PM'' | ||
*'''Interviewee:''' Robert Byrne | *'''Interviewee:''' Robert Byrne | ||
*'''Trial: ''' ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents | *'''Trial: ''' ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents | ||
| Line 130: | Line 115: | ||
*'''Interviewee:''' Cheol Whan Lee | *'''Interviewee:''' Cheol Whan Lee | ||
*'''Trial: ''' 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel | *'''Trial: ''' 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel | ||
===1:15 PM=== | ===1:15 PM=== | ||
| Line 136: | Line 120: | ||
*'''Interviewee:''' Flavio Ribichini | *'''Interviewee:''' Flavio Ribichini | ||
*'''Trial: ''' CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation | *'''Trial: ''' CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation | ||
===1:45 PM=== | ===1:45 PM=== | ||
| Line 142: | Line 125: | ||
*'''Interviewee:''' Josef Veselka | *'''Interviewee:''' Josef Veselka | ||
*'''Trial: ''' STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina | *'''Trial: ''' STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina | ||
===2:15 PM=== | ===2:15 PM=== | ||
| Line 148: | Line 130: | ||
*'''Interviewee:''' Patrick Ohlmann | *'''Interviewee:''' Patrick Ohlmann | ||
*'''Trial: ''' MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI | *'''Trial: ''' MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI | ||
===2:45 PM=== | ===2:45 PM=== | ||
| Line 154: | Line 135: | ||
*'''Interviewee:''' Junbo Ge | *'''Interviewee:''' Junbo Ge | ||
*'''Trial: ''' NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI | *'''Trial: ''' NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI | ||
===3:15 PM=== | ===3:15 PM=== | ||
| Line 160: | Line 140: | ||
*'''Interviewee:''' Giulio Guagliumi | *'''Interviewee:''' Giulio Guagliumi | ||
*'''Trial: ''' OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT | *'''Trial: ''' OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT | ||
===3:45 PM=== | ===3:45 PM=== | ||
| Line 166: | Line 145: | ||
*'''Interviewee:''' Josep Rodes-Cabau | *'''Interviewee:''' Josep Rodes-Cabau | ||
*'''Trial: ''' The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis | *'''Trial: ''' The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis | ||
===4:15 PM=== | ===4:15 PM=== | ||
| Line 172: | Line 150: | ||
*'''Interviewee:''' Dirk Walter | *'''Interviewee:''' Dirk Walter | ||
*'''Trial: ''' PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease | *'''Trial: ''' PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease | ||
| Line 183: | Line 160: | ||
*'''Interviewee:''' Simon Redwood | *'''Interviewee:''' Simon Redwood | ||
*'''Trial: ''' BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI | *'''Trial: ''' BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI | ||
===11:00 AM=== | ===11:00 AM=== | ||
| Line 189: | Line 165: | ||
*'''Interviewee:''' Arnold Seto | *'''Interviewee:''' Arnold Seto | ||
*'''Trial: ''' FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access | *'''Trial: ''' FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access | ||
===12:30 PM=== | ===12:30 PM=== | ||
| Line 195: | Line 170: | ||
*'''Interviewee:''' Rolf Michels | *'''Interviewee:''' Rolf Michels | ||
*'''Trial: ''' DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI | *'''Trial: ''' DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI | ||
===1:00 PM=== | ===1:00 PM=== | ||
| Line 202: | Line 176: | ||
*'''Trial: ''' 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents | *'''Trial: ''' 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents | ||
2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI | 2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI | ||
===1:30 PM=== | ===1:30 PM=== | ||
| Line 208: | Line 181: | ||
*'''Interviewee:''' Henry Krum | *'''Interviewee:''' Henry Krum | ||
*'''Trial: ''' SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension | *'''Trial: ''' SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension | ||
''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]'' | ''[[TCT 2009 schedule#Click on Date for Detailed Schedule|Return to top]]'' | ||
Revision as of 15:49, 28 August 2009
Here is the page we will use to coordinate the TV events at TCT 2009. The filming will take place in Room East 264 at the Moscone Convention Center.
Click on Date for Detailed Schedule
Tuesday September 22, 2009
12:30 PM
12:30 PM - 1:00 PM
- Interviewee: Peter Smits
- Trial: COMPARE. A Prospective, Randomized Trial of Everolimus-eluting vs. Paclitaxel-Eluting Stents
- Phone number:
1:00 PM
1:00 PM - 1:30 PM
- Interviewee: Shamir Mehta
- Trial: CURRENT-PCI OASIS 7. A Prospective, Randomized, Placebo-Controlled Trial of High- vs. Standard-Dose Clopidogrel and High- vs. Low-Dose Aspirin in Patients Undergoing PCI for ACS
2:00 PM
2:00 PM - 2:30 PM
- Interviewee: John Spertus
- Trial: NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
2:30 PM
2:30 PM - 3:00 PM
- Interviewee: Eberhard Grube
- Trial: BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
3:00 PM
3:00 PM - 3:30 PM
- Interviewee: David Allie
- Trial: CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
3:30 PM
3:30 PM - 4:00 PM
- Interviewee: Douglas Losordo
- Trial: ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
4:00 PM
4:00 PM - 4:30 PM
- Interviewee: Gary Ansel
- Trial: ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
4:30 PM
4:30 PM - 5:00 PM
- Interviewee: Ran Kornowski
- Trial:
5:00 PM
5:00 PM - 5:30 PM
- Interviewee: Francesco Prati
- Trial: COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT
Wednesday September 23, 2009
8:30 AM
8:30 AM - 9:00 AM
- Interviewee: William Fearon
- Trial: FAME: 2-Year Follow-up From a Prospective, Randomized Trial of FFR-Guided vs. Angiography-Guided PCI in Patients with Multivessel Coronary Artery Disease
9:00 AM
9:00 AM - 9:30 AM
- Interviewee: Lorenz Raber
- Trial: SIRTAX-LATE. 5-Year Clinical and Angiographic Follow-up from a Prospective, Randomized Trial of Sirolimus-Eluting and Paclitaxel-Eluting Stents
9:30 AM
9:30 AM - 10:00 AM
- Interviewee: Volker Klauss
- Trial: LEADERS. 2-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
10:00 AM
10:00 AM - 10:30 AM
- Interviewee: Deepak Bhatt
- Trial: 1) COGENT. A Prospective, Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving Aspirin and Clopidogrel
2) CHARISMA GENOMICS SUBSTUDY. Evaluation of the CYP2C19 Polymorphism in a Prospective, Randomized, Placebo-Controlled Trial of Chronic Clopidogrel Use for Primary and Secondary Prevention
10:30 AM
10:30 AM - 11:00 AM
- Interviewee: David Cohen
- Trial: TRITON-TIMI 38 ECONOMIC SUBSTUDY. Cost-Effectiveness of Prasugrel vs. Clopidogrel From a Prospective, Randomized Trial of Patients with ACS Undergoing PCI
11:00 AM
11:00 AM - 11:30 AM
- Interviewee: Chris Cannon
- Trial: PLATO INVASIVE. A Prospective, Randomized, Placebo-Controlled Trial of Ticagrelor vs. Clopidogrel in Patients with ACS Managed with an Invasive Strategy
12:00 PM
12:00 PM - 12:30 PM
- Interviewee: Robert Byrne
- Trial: ISAR-DESIRE 2. A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents for Treatment of Restenosis in Sirolimus-Eluting Stents
Thursday September 24, 2009
12:45 PM
12:45 PM - 1:15 PM
- Interviewee: Cheol Whan Lee
- Trial: 1) ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents; 2) CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
1:15 PM
1:15 PM - 1:45 PM
- Interviewee: Flavio Ribichini
- Trial: CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
1:45 PM
1:45 PM - 2:15 PM
- Interviewee: Josef Veselka
- Trial: STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
2:15 PM
2:15 PM - 2:45 PM
- Interviewee: Patrick Ohlmann
- Trial: MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
2:45 PM
2:45 PM - 3:15 PM
- Interviewee: Junbo Ge
- Trial: NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
3:15 PM
3:15 PM - 3:45 PM
- Interviewee: Giulio Guagliumi
- Trial: OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
3:45 PM
3:45 PM - 4:15 PM
- Interviewee: Josep Rodes-Cabau
- Trial: The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
4:15 PM
4:15 PM - 4:45 PM
- Interviewee: Dirk Walter
- Trial: PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
Friday September 25, 2009
10:30 AM
10:30 AM - 11:00 AM
- Interviewee: Simon Redwood
- Trial: BCIS-1. A Prospective, Randomized Trial of Intraaortic Balloon Pump Counterpulsation in High-Risk Patients Undergoing PCI
11:00 AM
11:00 AM - 11:30 AM
- Interviewee: Arnold Seto
- Trial: FAUST. A Prospective, Randomized Trial of Ultrasound-Guided vs. Standard Femoral Arterial Access
12:30 PM
12:30 PM - 1:00 PM
- Interviewee: Rolf Michels
- Trial: DEBATER. A Prospective, Randomized Trial of Drug-Eluting vs. Bare Metal Stents With or Without Abciximab in STEMI
1:00 PM
1:00 PM - 1:30 PM
- Interviewee: Gregg Stone
- Trial: 1) SPIRIT IV. A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents
2) PROSPECT. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque, 3) HORIZONS-AMI. 2-Year Follow-up From a Prospective, Randomized Trial of Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Metal Stents in STEMI
1:30 PM
1:30 PM - 2:00 PM
- Interviewee: Henry Krum
- Trial: SYMPLICITY I. 1-Year Results Following Sympathetic Renal Denervation in Refractory Hypertension